Middle East Pharmaceutical Industries Company (TADAWUL: 4016)

Market Cap	2.58B
Revenue (ttm)	366.87M
Net Income (ttm)	79.45M
Shares Out	20.00M
EPS (ttm)	3.97
PE Ratio	32.47
Forward PE	27.45
Dividend	1.50 (1.16%)
Ex-Dividend Date	Sep 2, 2024

Volume	55,494
Open	128.80
Previous Close	128.20
Day's Range	128.00 - 130.20
52-Week Range	90.20 - 197.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About Middle East Pharmaceutical Industries Company

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 543
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2023, Middle East Pharmaceutical Industries Company's revenue was 338.44 million, an increase of 11.82% compared to the previous year's 302.66 million. Earnings were 65.83 million, an increase of 10.72%.